HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates
HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ -- HKeyBio has established HKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration...
HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ -- HKeyBio has established HKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.